Erudio Healtherudio.com
Drug
Sacituzumab tirumotecan trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying sacituzumab tirumotecan: OptiTROP-Lung06 and TroFuse-005. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 15 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| TroFuse-005 NCT06132958 · Merck Sharp & Dohme LLC | endometrial cancer after platinum-based chemotherapy and immunotherapy | Phase 3 | 284 | 74 | Standard | Nov 13, 2026 | Preview |
| OptiTROP-Lung06 NCT06711900 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | first-line PD-L1-negative advanced non-squamous non-small cell lung cancer | Phase 3 | 13 | 8 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| OptiTROP-Lung05 NCT06448312 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. DeepView → | first-line PD-L1-positive advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| OptiTROP-Breast01 NCT05347134 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. DeepView → | Not given | Phase 3 | Deep | View | |||
| OptiTROP-Lung04 NCT05870319 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. DeepView → | Not given | Phase 3 | Deep | View | |||
| TroFuse-010 NCT06312176 · Merck Sharp & Dohme LLC StandardView → | HR+/HER2- unresectable locally advanced or metastatic breast cancer | Phase 3 | Standard | View | |||
| TroFuse-033 NCT06952504 · Merck Sharp & Dohme LLC StandardView → | mismatch repair-proficient endometrial cancer, first-line maintenance | Phase 3 | Standard | View | |||
| SKB264-II-06 NCT05642780 · Klus Pharma Inc. StandardView → | solid tumors | Phase 2 | Standard | View | |||
| SETHY NCT07068542 · Zhejiang Provincial People's Hospital FocusedView → | advanced thyroid cancer | Not applicable | Focused | View | |||
| NCT05631262 NCT05631262 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. FocusedView → | advanced solid tumors | Phase 2 | Focused | View | |||
| TroFuse-007 NCT06170788 · Merck Sharp & Dohme LLC FocusedView → | first-line metastatic NSCLC with PD-L1 TPS ≥50% | Phase 3 | Focused | View | |||
| TroFuse-032 NCT06966700 · Merck Sharp & Dohme LLC FocusedView → | early-stage triple-negative or HR-low+/HER2− breast cancer | Phase 3 | Focused | View | |||
| TroFuse-031 NCT07419295 · Merck Sharp & Dohme LLC FocusedView → | pretreated locally advanced/metastatic urothelial carcinoma | Phase 3 | Focused | View | |||
| ALTER-L043 NCT05351788 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. FocusedView → | Not given | Phase 2 | Focused | View | |||
| TroFuse-011 NCT06841354 · Merck Sharp & Dohme LLC FocusedView → | previously untreated PD-L1 CPS<10 advanced triple-negative breast cancer | Phase 3 | Focused | View | |||
| NCT05445908 NCT05445908 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. FocusedView → | Not given | Phase 2 | Focused | View | |||
| TroFuse-019 NCT06312137 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 3 | Focused | View | |||